quality and competence) certified," Marty Boom. "Our facilities based in Bangalore and Chennai are ISO 9001:2015 and ISO 27001:2013 certified. Our facilities have been successfully audited by health authorities (like US FDA) and clients over 40 times, with no significant findings." Marty Boom adds, "Around 25% of our global team comprise of domain experts (medical doctors, PhDs, and biostatisticians), with an average of ten years of hands-on experience in clinical trials and drug development. We have been recognized as Major Contenders in the Everest Group's Pharmacovigilance and Complaint Management Operations ­ Services PEAK Matrix® Assessment 2021." Navitas Life Sciences provides high-quality, end-to-end, Clinical, Regulatory, and Safety services, and their offerings are backed by deep domain experience and unique technical expertise. They are proud to have supported 10+ COVID-19 clinical trials that promise to bring effective therapies to market in humanity's time of need. Time and again, they have impressed clients with their ability to deliver on time, enabling them to meet stringent deadlines and get to market quickly. This is because they augment their clinical capabilities with technology enablers to allow seamless execution and quick results. A stellar example of this is a recent engagement with a mid-sized pharma company looking to bring a new therapy to the market to treat moderate to severe COVID-19 cases. "We accomplished study milestones even before the committed timeline, provided our client with real-time data dashboards to enable them to make quick decisions, and delivered effective remote monitoring at site level while maintaining high quality standards," explains Marty Boom. "Our excellent delivery was highly appreciated by our client, for whom we are now the preferred partner for multiple COVID-19 studies." During the recent COVID-19 pandemic, OneClinical®, a proprietary Analytics platform that provides near real-time data insight to take proactive action, has proven highly effective in enabling the remote monitoring of clinical trials, allowing us to support both COVID-19 trials, as well as multiple non-COVID clinical trials in oncology, ophthalmology, and infectious diseases areas. "We managed Pharmacovigilance for several COVID-19 trials and performed the submission management and publishing activities for one of the leading vaccines," says Marty Boom. "We pride ourselves on offering our clients the perfect blend of clinical capability, technology expertise and regulatory services to run virtual trials in these unprecedented times."
< Page 8 | Page 10 >